Glossodynia

Summary

Glossodynia (MONDO:0043237) is a disease and 1 clinical trial. Top therapeutic interventions include clonazepam. A subtype of tongue disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	glossodynia
Mondo ID	MONDO:0043237
MeSH	D005926
ICD-10-CM	K14.6
ICD-11	1755751917
SNOMED CT	30731004
UMLS	C0017672
MedGen	6617
Is cancer (heuristic)	no

Also known as: Glossalgias · glossodynia · Glossodynias · Glossopyroses · glossopyrosis

Disease family

This is a subtype of tongue disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › mouth disorder › tongue disorder › glossodynia

Related subtypes (8): hypertrophy of tongue papillae, glossitis, hairy tongue, ankyloglossia, fissured tongue, isolated congenital hypoglossia/aglossia, digestive duplication cyst of the tongue, tongue neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04884503	PHASE2	COMPLETED	Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLONAZEPAM	4	1